These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27160948)

  • 1. A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future?
    Chapple CR; Kelleher CJ; Evans CJ; Kopp Z; Siddiqui E; Johnson N; Mako M
    Eur Urol; 2016 Nov; 70(5):799-805. PubMed ID: 27160948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review.
    Johnston KM; Walker DR; Lakzadeh P
    Adv Ther; 2019 Mar; 36(3):548-562. PubMed ID: 30715686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the Overactive Bladder-Bladder Assessment Tool (OAB-BAT): A Potential Alternative to the Standard Bladder Diary for Monitoring OAB Outcomes.
    Chapple C; Kelleher C; Siddiqui E; Andrae DA; Johnson N; Payne C; Homma Y; Hakimi Z; Evans C; Lyn N; Kopp Z
    Eur Urol Focus; 2021 Sep; 7(5):1176-1183. PubMed ID: 33451958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study.
    Crosby RD; Mathias SD; Marshall TS
    Int J Clin Pract; 2011 Feb; 65(2):211-8. PubMed ID: 21235700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder.
    Barsdorf AI; Carlsson M; Bushmakin AG; Quinn S; Cappelleri JC; Pleil A
    Int Urogynecol J; 2017 Dec; 28(12):1857-1863. PubMed ID: 28378111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
    Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
    J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between psychological stress levels and the severity of overactive bladder symptoms.
    Lai H; Gardner V; Vetter J; Andriole GL
    BMC Urol; 2015 Mar; 15():14. PubMed ID: 25887525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment.
    Peyronnet B; Mironska E; Chapple C; Cardozo L; Oelke M; Dmochowski R; Amarenco G; Gamé X; Kirby R; Van Der Aa F; Cornu JN
    Eur Urol; 2019 Jun; 75(6):988-1000. PubMed ID: 30922690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
    Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
    Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
    BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.